Actively Recruiting
Study of Pemigatinib Combined With Atezolizumab and Bevacizumab for Advanced Cholangiocarcinoma With FGFR2 Fusion
Led by M.D. Anderson Cancer Center · Updated on 2026-08-17
25
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate whether pemigatinib combined with atezolizumab and bevacizumab can help control advanced cholangiocarcinoma with FGFR2 fusion. The study focuses on assessing the treatments antitumor activity through objective response rates and examines safety, recommended dosing, duration of response, progression-free survival, overall survival, and clinical benefit rates. It also explores immune changes and genomic markers related to treatment response and resistance. Participants receive pemigatinib orally, atezolizumab, and bevacizumab by oral and intravenous routes. The study has two parts Part 1 tests up to two doses of pemigatinib to find the recommended dose, with small groups receiving different dose levels Part 2 treats participants with the recommended dose identified in Part 1. The combination of drugs is studied to determine safety and dosing for FGFR-altered metastatic cholangiocarcinoma. Throughout the study, participants undergo regular evaluations including tumor scans, laboratory tests, and biomarker assessments. Researchers monitor safety and adverse events for about one year from treatment start. The study measures tumor response using standard criteria, records duration of response and survival data, and studies immune and genetic changes in blood samples. Participants are followed until study completion, which may last up to several years.
CONDITIONS
Brief Title
Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
Research Team
S
Sunyoung Lee, MD,PHD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here